Clinical trials: At Risk for HIV
HIV, Substance Use
Employing eSBI in HIV Testing for At-risk Youth
The purpose of this study is to assess the feasibility, acceptability and test the initial efficacy of eSBI, (electronic screening and brief intervention for alcohol use) coupled with STTR (Seek, Test, Treat, and Retain) in…
- Trial name
- NCT02703116
- Testing
- Alcohol Use BI, Nutrition Intervention
- Where
- 3 sites in United States
- Volunteers
- 464 people, healthy volunteers welcome
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW).
- Trial name
- PURPOSE 1 (NCT04994509)
- Testing
- Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF
- Where
- 28 sites in South Africa, Uganda
- Volunteers
- 5,368 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
HIV Infections, Contraception
A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention
The study design is a single-site, two-arm, randomized, open-label crossover trial in 30 AGYW aged 16-24 in Chitungwiza (Harare), Zimbabwe.
- Trial name
- 952 (NCT04778514)
- Testing
- Dual Prevention Pill, PrEP and combined oral contraceptive (COC) as two separate tablets
- Where
- Zimbabwe
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Population Council
HIV Infections
A Crossover Adherence and Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention
A randomized, crossover study to compare adherence, preference and acceptability of an over-encapsulated dual prevention pill (DPP capsule) containing oral pre-exposure prophylaxis (PrEP) and a combined oral contraceptive (COC)…
- Trial name
- NCT04778527
- Testing
- Dual Prevention Pill, PrEP tablet and a COC as two separate tablets
- Where
- South Africa
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Population Council
Substance Use Disorders, HIV Infections
Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People
This is a multi-phased study, funded through a National Institute on Drug Abuse (NIDA) K24 grant that aims to ultimately refine a virtual reality tool through qualitative and quantitative research targeting HIV and substance…
- Trial name
- NCT05816083
- Testing
- Virtual Reality Tool
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
HIV Preexposure Prophylaxis
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who…
- Trial name
- Impower-024 (NCT04652700)
- Testing
- ISL, FTC/TDF, FTC/TAF
- Where
- 25 sites in United States, Brazil and 5 more
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Adherence, Substance Abuse
Targeting PM to Improve HIV Adherence in Adolescents at Risk for Substance Abuse
Medication adherence rates among youth living with HIV are inadequate to effectively manage the disease, and novel interventions grounded in basic behavioral sciences are needed.
- Trial name
- NCT01959217
- Testing
- PM Component Text Reminders
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Wayne State University
Mother to Child HIV Transmission
HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure
Principal objective Assess the operational efficacy of a strategy combining early diagnosis and preventive antiretroviral treatment systematically reinforced from the birth* among infants at high risk of infection with HIV** .
- Trial name
- DIAVINA (NCT03642704)
- Testing
- Reinforced preventive ARV therapy
- Where
- Guinea
- Volunteers
- 56 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Sexual Risk
Young Women's CoOp Study
The purpose of this study is to test the efficacy of a cultural-, age- and gender-focused Human Immunodeficiency Virus (HIV) prevention intervention in reducing risk behaviors among African-American young women relative to…
- Conditions
- HIV, Sexual Risk, Sexually Transmitted Diseases, Substance Abuse
- Trial name
- YWC (NCT01224184)
- Testing
- Young Women's CoOp, Staying Healthy and Eating Well
- Where
- 2 sites in United States
- Volunteers
- 237 people
- Sponsor
- RTI International
Adherence, Medication, Adolescent Behavior
Youth-focused Strategies to Promote Adherence to Pre-exposure Prophylaxis Among Youth At-risk for HIV in Thailand
A randomized controlled clinical trial looking at the effect of use of a mobile phone application in addition to standard care compared to standard care alone at a youth-friendly clinic in young men who have sex with men and…
- Conditions
- Adherence, Medication, Adolescent Behavior, HIV Prevention, Sexual Health
- Trial name
- YouthPrEP (NCT03778892)
- Testing
- 'Project Raincoat' Mobile Phone Application
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
HIV Negative People Identified at Substantial Risk for HIV Infection
PrEP Demonstration Study in Swaziland
This stepped-wedge cluster-randomized trial is embedded in an 18-month observational cohort study that has the aim to assess the operationalization of oral Pre-Exposure Prophylaxis (PrEP) in Swaziland as an additional HIV…
- Trial name
- NCT03254550
- Testing
- PrEP Promotion Package
- Where
- 6 sites in Eswatini
- Volunteers
- 517 people, healthy volunteers welcome
- Sponsor
- Clinton Health Access Initiative Inc.
HIV-I, Human Immunodeficiency Virus Type 1
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection.
- Conditions
- HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
- Trial name
- Impower-022 (NCT04644029)
- Testing
- Islatravir, FTC/TDF
- Where
- 24 sites in United States, South Africa and 1 more
- Volunteers
- 730 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV, Sexually Transmitted Diseases
Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
This study will determine whether showing an educational DVD to people at sexually transmitted infection clinics can reduce incidence of new infections and risky sexual behaviors and improve overall health.
- Conditions
- HIV, Sexually Transmitted Diseases, HIV Infections
- Trial name
- NCT00947271
- Testing
- DVD 1, DVD 2
- Where
- United States
- Volunteers
- 1,010 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital